Tania Velez Calao, MD
Family Medicine · Miami, FLNPI 1942573316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novo Nordisk at 47.7% of the total. Reporting peaked in 2021 at $819 and has fallen 91.2% since, to $72 in 2024.
Across 78 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$419
- Johnson & Johnson$204
- AstraZeneca$172
- AbbVie$132
- Boston Scientific$59
- plus $257 from 9 others
What the payments were for
- Food & beverage$2,374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $1,132 |
| GSK | 20 | $419 |
| Johnson & Johnson | 6 | $204 |
| AstraZeneca | 3 | $172 |
| AbbVie | 7 | $132 |
| Boston Scientific | 1 | $59 |
| Bayer | 2 | $52 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Amgen | 2 | $41 |
| Microport CRM USA Inc | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,374 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 13 | $17,885 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $600 |
| Methylprednisolone | 77 | $566 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 59 | $537 |
| Doxycycline Monohydrate | 14 | $175 |
| Fluoxetine Hcl | 13 | $163 |
| Irbesartan | 23 | $163 |
| Sucralfate | 12 | $146 |
| Doxycycline Hyclate | 13 | $130 |
| Ciprofloxacin Hcl | 11 | $128 |
| Losartan Potassium | 27 | $111 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $102 |
| Levothyroxine Sodium | 24 | $94 |
| Atorvastatin Calcium | 27 | $88 |
| Montelukast Sodium | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.